Anchen Announces Approval of Generic Version of Wellbutrin XL(R).IRVINE, Calif. -- Anchen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application abbreviated new drug application Pharmacology An application made in the US by a pharmaceutical company requesting authority to market a 'new' drug for which both its therapeutic indications and formulation were previously approved by the FDA in another similar to market its generic version of Biovail Corporation's (NYSE NYSE See: New York Stock Exchange :BVF; TSX:BVF) anti-depressant Wellbutrin XL[R] (Bupropion hydrochloride) Extended-Release Tablets, 150 mg and 300 mg. Commenting on today's approval, Dr. Chih-Ming Chen, Chief Executive Officer and Chairman of Anchen said, "We are extremely pleased to receive FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of our generic version of Wellbutrin XL[R]. Today's approval represents an important milestone in Anchen's development and commitment to offer high quality products for consumers at affordable cost." Anchen is still involved in ongoing litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. concerning this product. In August 2006, the District Court granted Anchen's motion for summary judgment motion for summary judgment n. a written request for a judgment in the moving party's favor before a lawsuit goes to trial and based on recorded (testimony outside court) affidavits (or declarations under penalty of perjury), depositions, admissions of fact, answers of non-infringement. Biovail has appealed the District Court decision. About Anchen Anchen Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of extended release generic products and brand name novel formulations of existing drugs where there are less competition and higher margins. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion